Tracy Li
Good morning, everyone. This is Tracy Li from Waterdrop Investor Relations.
It's my pleasure to welcome everyone to Waterdrop fourth quarter and fiscal year 2025 earnings conference call. All participants are in a listen-only mode in our English line.
As a reminder, today's conference call is being recorded. Please note that discussion today will contain forward-looking statements made under the safe harbor provisions of the U.S.
Private Securities and Litigation Reform Act of 1995. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from our current expectations.
Potential risks and uncertainties include, but not limited to, those outlined in our public filings with the SEC. The company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
Also, this call includes discussion of certain non-GAAP measures. Please refer to our earnings release for reconciliation between non-GAAP and GAAP.
Joining us today on the call are Mr. Shen Peng, our founder, chairman, and CEO; Mr.
Ran Wei, director and GM of insurance business; Mrs. Xiaoying Xu, head of finance department; and Mrs.
Jieru Li, board secretary. We'll be happy to take some of the questions in the Mandarin line at the end of the conference call.
Now let's invite our CEO Shen Peng to start.
Shen Peng
Dear investors and analysts, thank you for joining Waterdrop fourth quarter and fiscal year 2025 earnings conference call. Looking back at 2025, we executed firmly on our AI-plus-insurance strategy, delivering tangible progress in both AI application and business growth.
Our financial performance were robust. We saw significant top-line and bottom-line expansion, further solidify our core fundamentals.
For the fiscal year 2025, our revenue reached 3.98 billion, up 43.5%, while net profit attributable to ordinary shareholders reached 570 million, representing year-on-year growth of 54.8%. Notably, we met our guidance to the market and have now delivered GAAP profitability for 16 consecutive quarters.
Our insurtech segment was a standout, with revenue surging 51.3% and an operating margin of roughly 18%. Furthermore, our LLM integration significantly accelerated the value of our medical crowdfunding platform.
Our platform has raised funds for 3.68 million patients since its launch, and our digital clinical trial solutions enrolled over 4,000 patients this year. Reflecting the strong performance in the second half of 2025, our board approved our fifth cash dividend of $0.03 per ADS, totaling $10.8 million.
This will be paid in late April to early May to shareholders of record as of April 24, 2026, U.S. Eastern Time.
Meanwhile, our share repurchase program remains on track, with 60.7 million ADSs repurchased for about $118 million through the end of February 2026. On the technology front, we are accelerating our shift to become an AI-native company.
As of year-end 2025, we filed 72 LLM-related patent applications, including nine international ones. Throughout the year, we deployed the multi-model AI agent spanning text, voice, and virtual interactions across all core workflows, from acquisition and conversation, sales productivity, and customer service to quality control and R&D.
Every stage is now production-ready, delivering measurable operating gains. These capabilities are unified under the Waterdrop C.AI, our company-wide platform for configuring neural-specific agents, now also open to industry partners.
Beyond internal use, we are pioneering open collaboration infrastructure via our Waterdrop Guardian AI Copilot, which is called CloudSphere. Built on a distributed architecture design, our CloudSphere enables different AI agents to autonomously communicate and collaborate.
Early demos have already validated its core workflow, seamlessly multi-round dialogue and automated task handover between AI agents. In terms of ESG, we partnered with 119 organizations to launch over 15,500 projects, earning global recognition for our poverty reduction efforts and upgrading our ESG rating to A+.
As we enter our 10th anniversary in 2026, our goal is to move beyond just using AI tools to becoming a truly AI-native company. We aim to digitally reconstruct our entire value chain, embedding AI as a structural competitive advantage.
We expect to sustain the momentum this year with moderately higher investment in marketing and AI, targeting double-digit growth in both revenue and profit. Now I will pass to Ran Wei to introduce the development of insurance business.
Wei Ran
Thanks, Shen Peng. In the fourth quarter, our insurance business continued its strong momentum.
Insurance-related income surged 125% year-on-year to 1.31 billion, while operating profit grew 42% year-on-year to 160 million. On the traffic side, we have sharpened our real-time user identification.
Leveraging our self-deployed 50-millisecond data models, we can now capture potential user attributes with millisecond precision in high-concurrency traffic. This allows for hourly hot updates and rapid A/B testing, which had significantly improved the accuracy of our high-quality traffic filtering and laid a solid foundation for our FYP growth.
Regarding products supply, our market-first Canbingbao launched version 2.0 this quarter. New zero deductible features now cover both high-burden long-term medical costs and routine medical expenses.
Additionally, our pre-existing condition products gained strong traction, with FYP up nearly 70%, while disability insurance contributed about 100 million FYP, validating our long-term strategy. Most importantly, AI is now embedded in every node of our service chain.
On the user side, our AI Pro insurance agent on the mini program drove a 33% sequential increase in premiums, while our AI medical insurance experts generated over 50 million in FYP, up 145% quarter-on-quarter. We have also extended this AI capability to standard health products on WeChat, generating incremental monthly premiums of over 1 million.
For human agent empowerment, our live planner copilot has cumulatively assisted in over 370,000 inquiries as of this quarter end. Our Waterdrop C.AI platform is now fully operational, and having completed the fourth-quarter rollout of the core module as workflow agents, batch testing, and proactively task triggers.
This infrastructure powers our tell-all AI planner deployed across both WeChat official accounts and mini programs to handle product recommendations, business qualification, and user-agent matching. We have even opened this platform to our partners like insurers to uplift the industry-wide efficiency.
In after-sales, our AI customer service agents handled over 1.4 million inquiries per month. AI-powered quality control copilot took per-capita efficiency to 2.75 times that of the manual-only baseline.
This concludes the insurance business update for the fourth quarter. Now I will pass to board secretary Yelu to introduce the progress of our medical crowdfunding and healthcare businesses.
Jieru Li
Thank you, Ran Wei. As of the end of 2025, approximately 490 million people have cumulatively donated a total of 72.3 billion to 3.68 million patients through Waterdrop medical crowdfunding platform.
In this quarter, while maintaining robust platform governance and user experience, we strengthened risk control in two key areas. To protect our user privacy, we have fully upgraded our system with large language models capable of identifying sensitive data and applying dynamic data masking in real time.
For critical information frequently seen in the campaign, like user ID numbers, bank accounts, and the medical record IDs, we have moved from the manually redaction to automatically detection and masking. This guarantees end-to-end security for user data across our entire platform, fundamentally preventing any risk of information theft.
Secondly, on content authenticity, we deployed a new model combining medical knowledge graph with credential validation. This system can cross-reference the clinical logic to precisely identify the fabricated receipts, ensuring every donation reaches those patients who are truly in need.
On the user service front, we launched a standardized inquiry toolkit to bring fully clarity to our service scope, fee structures, and campaign deadlines. This initiative reinforced our commitment to transparency and ensure our users are fully informed.
Moving to the healthcare business, our E-Find platform sustained high-quality growth, partnered with 224 pharmaceutical companies and CROs, and enrolled in a record of 14,555 cumulative patients, initiating 131 new programs, once again setting a new quarterly enrollment record. This quarter, we achieved a major milestone that Waterdrop's proprietary drug-patient matching technology, the first of its kind in China, was officially granted a national invention patent.
By combining deep neural networks with natural language processing, our technology achieves end-to-end precision matching between patients and clinical trials. It uses rule-based filtering for structured data like age and lab results while analyzing unstructured medical records against the trial criteria to uncover the hidden match.
The dual-engine approach shrinks the weeks of the manually screening workload down to minutes, strongly accelerating the clinical trial process. Building on this, we significantly expand our reach while continuing to grow our patient base in complex and rare cancer cases.
Digital clinical trial revenue related to chronic disease surged 30% this quarter compared to the previous three-quarter average. This expanded capabilities across multiple disease and domains, and have laid a solid foundation for our sustainable long-term growth.
Now I will pass to Xiaoying, our head of finance department, to discuss our financial performance in this quarter.
Xiaoying Xu
Thanks, Yelu. Hello, everyone.
I will now walk you through our financial highlights for the fourth quarter and the fiscal year 2025. Before I go into details, please be reminded that all numbers quoted here will be in RMB.
Please refer to our earnings release for detailed information on our financial performance on both the year-on-year and quarter-over-quarter basis, respectively. In the fourth quarter, our performance growth accelerated significantly, with quarterly revenue more than doubling year-on-year to 1.41 billion, up 105.5%.
For the full year 2025, revenue reached 3.98 billion, up 43.5% year-on-year, concluding the year on a strong note. By segment, the insurance business remained a stable cornerstone, with full-year insurance-related income reaching approximately 3.58 billion, up 51.3% year-on-year.
The other segments accounted for about 10.1% of the total revenue, with medical crowdfunding service fees at 260 million and digital clinical trial solution income at 118 million. Operating costs for the quarter reached 608 million, up 109.2% year-on-year, driven by a 320 million increase in cost and referral and service fees and a 26.8 million rise on SMS costs.
Driven by rapid business expansion, operating costs and expenses in the fourth quarter rose to 1.33 billion, up 109.4% year-on-year. For the full year, operating costs and expenses increased 39.1% from 2024, below the pace of revenue growth.
Sales and marketing expenses was roughly 510 million, up 178.4% year-on-year, with significant improvement in customer acquisition efficiency. The company proactively scaled up investments, resulting a roughly 280 million year-on-year increase in marketing expenses for third-party traffic channels.
G&A expenses were 77.1 million, a modest year-on-year increase of 4.6%, mainly due to a 6.7 million increase in allowance of credit losses and 5.2 million in professional service fees, partially offset by 6.5 million reductions in personnel costs. Research and development expenses were approximately 66.2 million, up 21.9% year-on-year, primarily driven by a 6.4 million increase in personnel costs and a 5.8 million rise in cloud service fees.
Company's profits improved significantly year-on-year. Net profit attributable to the company's ordinary shareholders for the fourth quarter reached 152 million, up 52.7% year-on-year.
For full year, the net profit attributable to ordinary shareholders reached about 570 million, up 54.8%. The company maintained ample cash position of about 3.25 billion, 3.25 billion as of the end of 2025, providing a strong support for our future growth.
This conclude our financial overview for the fourth quarter and the fiscal year 2025.
Tracy Li
Ladies and gentlemen, with that, we will conclude today's conference call. We do thank you for joining.
Have a good time.
Already premium?